Navigation Links
Stereotaxis Reports First Quarter 2011 Financial Results
Date:5/2/2011

ty and efficacy over manual treatments.  In addition, we continue to expect resolution of our imaging partner's supply issue that impacted first quarter installations will be completed in the second quarter 2011."

The Company generated global new capital orders in the first quarter 2011 of $7.1 million, compared to $7.2 million in capital orders placed during the first quarter 2010.  Global orders for the Niobe robotic system in the first quarter 2011 totaled $4.6 million, compared to $5.7 million in Niobe orders reported in the year ago quarter.  Odyssey system orders in the first quarter 2011 were $2.5 million, up 66.7% from the $1.5 million in Odyssey orders in the year ago quarter.  New capital orders from North America were $3.3 million, or 47% of total orders in the first quarter of 2011.  

Product Advancements to be Featured at Heart Rhythm Society's 32nd Annual Scientific SessionsStereotaxis announced that its new Stereotaxis Epoch™ platform, which enhances the efficiency and versatility of the Niobe system, will be unveiled at the Heart Rhythm Society's (HRS) 32nd Annual Scientific Sessions in San Francisco during May 5-7, 2011.  The Stereotaxis Epoch solution is designed to meet the broad range of clinical needs physicians face today and in the future.  Building on the strength of Magnetic Navigation's exceptional safety profile and significant radiation reduction, the Epoch platform features the latest technological breakthroughs in Magnetic Navigation, which will lead to faster, more efficient, and dynamic magnetic catheter control.

"We remain focused on developing solutions that meet the most critical needs of our customers, while supporting any preferred clinical treatment technique.  Epoch is designed to significantly reduce procedure time for all types of robotic-assisted EP procedures, especially for complex ablation procedures.  We believe the Epoch platform will enab
'/>"/>

SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Stereotaxis Introduces New Electrophysiology Platform: Epoch™
2. Stereotaxis to Present at Upcoming Investor Conferences
3. Stereotaxis Reports 2010 Financial Results, Provides 2011 Financial Outlook
4. Stereotaxis Announces First Worldwide Use of Remote Magnetic Navigation for Renal Ablation to Treat Hypertension
5. Stereotaxis to Report Fourth Quarter and Full Year 2010 Financial Results and Conduct Conference Call on February 28, 2011
6. Stereotaxis Announces CE Mark and First Human Case for Vdrive™
7. Stereotaxis Announces Expansion of Catheter Strategic Partnership
8. Stereotaxis Announces Global Initial Training Site at University of Chicago
9. Stereotaxis Completes $40 Million Credit Facility
10. Stereotaxis Announces Public Offering of Common Stock
11. Stereotaxis Receives Commitment to Increase and Extend Credit Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... Tianyin Pharmaceutical Co., Inc., (NYSE Amex: ... and markets patented biopharmaceutical, modernized traditional Chinese medicine, ... the senior management will host a conference call ... financial results at 8:30 a.m. E.T. on Tuesday, ...
... LEIPZIG, Germany, Feb. 8, 2011 Data from the ... the SUPERA® stent for peripheral arterial disease (PAD) of ... Leipzig Interventional Course (LINC).  The SUPERA stent is CE ...  In the United States the SUPERA stent is the ...
Cached Medicine Technology:Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2011 Second Quarter Earnings Conference Call on Tuesday, February 15, 2011 at 8:30 a.m. E.T. 2One-Year European Registry Data Released for Popliteal Stenting With SUPERA® 2One-Year European Registry Data Released for Popliteal Stenting With SUPERA® 3
(Date:7/9/2014)... most common type of lung cancer, researchers have uncovered ... in forming tumors. The new knowledge may expand treatments ... changes already are available or are in clinical trials. ... from The Cancer Genome Atlas (TCGA), including researchers at ... Medical School and other institutions, studied tumors from 230 ...
(Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
(Date:7/9/2014)... There has been a sharp increase in the ... using MyChart, the online, interactive service that allows patients ... healthcare providers, schedule appointments, and renew prescriptions. , Over ... MyChart each year increased five-fold, while the ... 10-fold, according to a study by Dr. David ...
(Date:7/9/2014)... and have a reputation for being highly toxic, but when ... being being found to offer potential health benefits in a ... dementia. A new compound (AP39), designed and made at the ... by targeting delivery of very small amounts of the substance ... Scientists in Exeter have already found that the compound protects ...
(Date:7/9/2014)... prescription labels handed out by pharmacists may be ... medication, according to new research by the University ... the Blind)., The study, published recently in the ... on prescription medications dispensed by pharmacies do not ... By simply following recommended guidelines for font size, ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... French . Robot-assisted surgery dramatically improves outcomes ... researchers at the Jewish General Hospital,s Lady Davis Institute ... post-operative complications and shorter hospital stays, robotic procedures also ... late 2010 in a series of studies in ...
... , WEDNESDAY, Jan. 12 (HealthDay News) -- People who have ... after receiving the results, whether they are positive or negative, ... or get screening tests that might modify that risk, despite ... in the Jan. 13 issue of the New England ...
... of Science (AAAS) has elevated four Dartmouth professors to the ... Dartmouth Medical School. Medical School faculty members Charles ... MD, join Dartmouth biologist C. Robertson McClung among the 504 ... eight other Dartmouth researchers to have earned the distinction. ...
... Jan. 12 (HealthDay News) -- Research in rats suggests that ... by persistent ringing or other noises in the ears. ... a result of hearing loss. In this study, U.S. ... variety of sound tones over an extended period of time. ...
... cancer with a relatively high degree of accuracy when applied ... cancer, according to a study in the January issue of ... was performed at the University of Washington and Seattle Cancer ... with 592 patients who were recently diagnosed with breast cancer ...
... Scientists are reporting a scientific basis for the long-standing belief ... other countries can prevent and treat cataracts, a clouding of ... of vision loss worldwide. Their study appears in Inorganic ... Wu, Fu-Yung Huang, Shih-Hsiung Wu and colleagues note that eye ...
Cached Medicine News:Health News:Robotic surgery of 'tremendous benefit' to patients, say JGH researchers 2Health News:Consumer Genetic Testing May Not Boost Users' Anxiety 2Health News:Consumer Genetic Testing May Not Boost Users' Anxiety 3Health News:Dartmouth Medical School faculty named fellows of the American Association for the Advancement of Science 2Health News:Animal Study Finds Nerve Stimulation May Thwart Tinnitus 2
GE's Signa Contour/i system uses the latest innovations from around the world to bring new standards in quality and value to MRI....
Intera 3.0T is the most compact high-field clinical whole-body MR system in the world, bringing 3.0T capabilities "out of the tunnel" and into the light of an open, patient-friendly design....
... The Akbarnia PDR Instruments ... surgeons negotiate in and around ... and reconstruction procedures. The instruments ... construction, a variety of angled ...
... Symphony Platelet Concentrate System is a ... of Platelet Concentrate (also referred to as ... Poor Plasma (PPP) from a small sample ... body's natural growth factors, which are found ...
Medicine Products: